We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Screening Assay Approved in China and Brazil

By LabMedica International staff writers
Posted on 18 Nov 2010
An assay used in markets around the globe to screen donated blood for human immunodeficiency virus (HIV) Type 1 and Hepatitis viruses types B and C, has been granted approval for use in China and Brazil.

Sensitivity combined with the fully integrated and automated Procleix Ultrio assay, which is run on the TIGRIS platform, simplifies workflow and improves efficiency in the lab, a critical component to ensure testing and results are completed on time.

Novartis Diagnostics (Basel, Switzerland) launched the Procleix Ultrio assay and the Procleix TIGRIS platform in China at the Chinese Society of Blood Transfusion (CSBT) meeting, which took place on November 4-6, 2010, in Chengdu, China. More...
In Brazil, Novartis featured the Procleix Ultrio assay and the Procleix TIGRIS platform during the HEMO-Brazil meeting, which took place November 5-8, 2010, in Brasilia.

The company is working closely with blood centers in China and Brazil to introduce Ultrio and TIGRIS and help add an additional layer of blood safety to the blood screening process. In China, Novartis Diagnostics is collaborating with the Ministry of Health as part of the 2010 China nucleic acid testing (NAT) pilot program, sharing knowledge and best practices with blood centers using the Procleix Ultrio and TIGRIS systems to test NAT in their blood centers.

Blood screening centers in China and Brazil currently receive 10 million and 4.3 million annual blood donations, respectively. Blood centers in both countries are incorporating additional layers of protection to the blood screening process to increase the safety of the blood supply from donor to patient.

Related Links:

Novartis Diagnostics





Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Online QC Software
Acusera 24•7
New
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.